Register for email alerts and news feeds:
This journal | BMJ Group
rss
Evidence-Based Medicine 2006;11:171; doi:10.1136/ebm.11.6.171
Copyright © 2006 by the BMJ Publishing Group Ltd.

Therapeutics

Review: selective COX 2 inhibitors increase vascular events more than placebo and naproxen but not more than other NSAIDs

Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302–8.[Abstract/Free Full Text]

Q Do selective cyclo-oxygenase-2 (COX 2) inhibitors increase risk of serious vascular events more than placebo or traditional non-steroidal anti-inflammatory drugs (NSAIDs)?

Clinical impact ratings GP/FP/Primary care *****{star}{star} IM/Ambulatory care ******* Haematology *****{star}{star} Rheumatology *******

Key Words: anti-inflammatory agents (non-steroidal) • atherosclerosis • cyclo-oxygenase 2 inhibitors • thrombosis

The first 150 words of the full text of this article appear below.

METHODS

Formula Data sources: Medline and EMBASE/Excerpta Medica (1966 to April 2005), US Food and Drug Administration website, and drug manufacturers.

Formula Study selection and assessment: randomised controlled trials (RCTs) >=4 weeks in duration that compared a selective COX 2 inhibitor with placebo or a traditional NSAID. 138 RCTs (n = 145 373) met the selection criteria. Investigators and manufacturers provided details on the number of vascular events and person time at risk.

Formula Outcomes: myocardial infarction (MI), stroke, and vascular death, and a composite end point of all vascular events.

MAIN RESULTS

Selective COX 2 inhibitors increased risk of all vascular events and MI, but not stroke (tableGo) or vascular death, more than placebo and naproxen. COX 2 inhibitors and non-naproxen NSAIDs did not differ for all vascular events, MI (tableGo), or vascular death. Risk of stroke was lower with COX 2 inhibitors (tableGo). When data from indirect and direct comparisons were . . . [Full text of this article]

Andreas Laupacis, MD

Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.